#cardiovascular

GLP-1 Beyond Weight Loss: How Semaglutide and Tirzepatide Are Rewriting Metabolic Medicine in 2026

Ozempic and Wegovy are weight loss drugs—but the science shows GLP-1 receptor agonists do far more: cardiovascular protection, neuroinflammation reduction, addiction modulation, and potential Alzheimer's prevention. Here's what the 2026 evidence actually says, including the muscle loss risk no one talks about.